Search - tctmd.com

Displaying 21 - 40 of 4569

Sort: Relevancy | Date

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

News Conference News TCT 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Yael L. Maxwell

November 07, 2025

SAVE-PCI: Small-Bore Percutaneous VAD Matches IABP in High-risk PCI

News Conference News TCT 2025

SAVE-PCI: Small-Bore Percutaneous VAD Matches IABP in High-risk PCI

November 06, 2025

What’s Going to Be Hot at AHA 2025?

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

News Daily News

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

November 04, 2025

News Industry News

SMT’s Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025

October 29, 2025

iFR-Guided Immediate PCI Not Superior to Deferred CMR-Guided Strategy in STEMI

News Conference News TCT 2025

iFR-Guided Immediate PCI Not Superior to Deferred CMR-Guided Strategy in STEMI

Yael L. Maxwell

October 28, 2025

Tailored Testing and Care Ease Angina for MINOCA Patients: PROMISE

News Conference News TCT 2025

Tailored Testing and Care Ease Angina for MINOCA Patients: PROMISE

October 28, 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

News Conference News TCT 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

October 28, 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

News Conference News TCT 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

Michael O'Riordan

October 28, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

News Conference News TCT 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

October 27, 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

News Conference News TCT 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

Michael O'Riordan

October 27, 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

News Conference News TCT 2025

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

Yael L. Maxwell

October 26, 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

News Conference News TCT 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

October 26, 2025

Mechanical Thrombectomy Outshines Anticoagulation Alone in STORM-PE

News Conference News TCT 2025

Mechanical Thrombectomy Outshines Anticoagulation Alone in STORM-PE

October 26, 2025

Left Distal Radial Access Doesn’t Reduce Radiation for Operators: DOSE

News Conference News TCT 2025

Left Distal Radial Access Doesn’t Reduce Radiation for Operators: DOSE

October 25, 2025

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

News Features

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

October 22, 2025

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

October 22, 2025

Getting Ready for a Heart Failure Polypill, Well Before the Data Are In

News Daily News

Getting Ready for a Heart Failure Polypill, Well Before the Data Are In

October 16, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.